



News Release

Pivotal Therapeutics Inc. Begins Trading on the OTCQX

FOR IMMEDIATE RELEASE

April 3, 2012

Woodbridge, Ontario, April 3, 2012 - Pivotal Therapeutics Inc. (OTCQX: PVTTF; CNSX: PVO), a specialty pharmaceutical company with a focus on the treatment of cardiovascular disease, is pleased to announce today that the company is now trading on the highest tier of the OTC Markets Group, OTCQX[®], under the trading symbol **PVTTF**, effective at the market open on Tuesday, April 3, 2012.

"We are very excited to not only be trading on a U.S. exchange, but to be trading on the OTC market's prestigious tier, OTCQX International. The OTCQX International, with its strong reputation, transparency, information, and improved liquidity offers a significant opportunity to further enhance and increase our U.S. presence," says Dr. George Jackowski, Chairman of Pivotal Therapeutics. "This is a significant milestone for Pivotal, as it will allow us to expand our shareholder base and increase U.S. Investor visibility."

"OTCQX provides services to companies which enable them to communicate with and engage their investors, while providing them with transparent trading and easy access to company information," said R. Cromwell Coulson, President and Chief Executive Officer of OTC Markets Group. "We are pleased to welcome Pivotal Therapeutics to OTCQX." Investors can find current financial disclosures and Real-Time Level 2 quotes for the Company on www.otcmarkets.com.

Sichenzia Ross Friedman Ference LLP, a New York based law firm, will serve as Pivotal Therapeutics' Principal American Liaison ("PAL") on OTCQX, responsible for providing guidance on OTCQX requirements and U.S. securities laws.

About Pivotal Therapeutics Inc.

With offices in Toronto, Canada and Boca Raton, Florida, Pivotal Therapeutics is a publicly traded (OTCQX: PVTTF; CNSX: PVO) specialty pharmaceutical company with a focus on the treatment of cardiovascular disease and overall health. Pivotal Therapeutics' lead product **VASCAZEN™** is a prescription only medical food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating Eicosapentaenoic (EPA) and Docosahexaenoic (DHA) to levels associated with reduced risk of cardiovascular complications.

OMAZEN™ is a >90% pure, proprietary EPA:DHA fatty acid formulation commercialized for sale and distribution in Canada for the maintenance of good health through elevating Omega-3 fatty acid levels. The unique formulation and dosage will be available to patients and consumers who realize the health benefits of Omega-3 supplementation with a quality product.

VASCAZEN™ is a >90% pure, proprietary EPA:DHA fatty acid formulation, protected by a series of both issued and pending US and foreign patents and commercialized by prescription only. This unique formulation will provide the cornerstone upon which a family of cutting edge combination products, with efficacy across a broad spectrum of cardiac care, will be commercialized.

About OTC Markets Group Inc.

[OTC Markets Group Inc.](http://www.otcmarkets.com) (OTCQX: OTCM) operates the world's largest OTC marketplace for equity securities. Our OTC Link[®] trading system delivers price transparency in over 10,000 securities and enables direct interaction between broker-dealers that provide liquidity and execution services. We organize the marketplace by categorizing the wide spectrum of OTC-traded companies into three tiers: OTCQX - The Intelligent Marketplace for the Best OTC



Companies; OTCQB® - The Venture Marketplace; and OTC Pink® - The Open Marketplace. Our information-driven platform makes it easy for investors to trade at the best price through the broker of their choice and empowers companies to build the best markets for their investors. To learn more about our Open, Transparent, and Connected marketplace, visit www.otcmarkets.com.

Disclosure Notice

The information contained in this document is as of April 3, 2012. This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause Pivotal's actual results to differ materially from those projected in such forward-looking statements. These statements can be identified by the use of words such as "will", "anticipate", "estimate", "expect", "project", "forecast", "intend", "plan", "believe", "project", "potential", and similar expressions with any discussion of future operating or financial performance or events. In particular, factors that could cause actual results to differ materially from those in forward looking statements include the following: Pivotal's inability to obtain additional financing on acceptable terms; growth in costs and expenses; inability to compete with others who provide comparable products; risk that the Company's products will not gain widespread market acceptance; risks relating to the Company's ability to maintain its CSNX listing. Forward-looking statements speak only as of the date made and are not guarantees of future performance. The Company undertakes no obligation to publicly update or revise any forward-looking statements contained in this document as a result of new information or future events or developments.

- # -

Investor Relations Contact:

Timothy J. Ryan
Managing Director
Phone: 212-242-7777
E-Mail: tryan@shorehamgroupllc.com

Company Contact:

Rachelle MacSweeney
President
Phone: 905-856-9797
E-Mail: rmacsweeney@pivotaltherapeutics.us

The Shoreham Group, LLC
www.shorehamgroupllc.com

Pivotal Therapeutics Inc.
www.pivotaltherapeutics.us

OTC Markets Media Contact:

Grace Keith
Phone: 212-896-4428
E-Mail: grace@otcmarkets.com

OTC Markets Group Inc.
www.otcmarkets.com
